AKT1 mutation

Apigenin and kaempferol showed potential as dual-targeting agents for colon cancer therapy. Cell culture and animal model studies in future are warranted to substantiate the mechanistic roles in tumor suppression.

P1, N=134, Active, not recruiting, Atavistik Bio, Inc | Recruiting --> Active, not recruiting

This study provides a regional molecular profile of advanced CRC in Bulgaria, highlighting a high prevalence of KRAS mutations and dMMR status, while underrepresentation of rare targetable alterations, likely due to limited use of broad molecular profiling. The association between stromal features and MMR status supports their potential role as surrogate markers in settings with constrained testing resources. Findings underscore the urgent need for equitable access to molecular diagnostics and targeted therapies to close the survival gap between Eastern and Western Europe.

P1/2, N=47, Not yet recruiting, Cancer Hospital of Shanxi Province; Cancer Hospital of Shanxi Province

In external transcriptomic validation (TCGA-CRC), GSEA indicated enrichment of interferon/inflammatory programs in TIGIT-high tumors, while CD155-high tumors preferentially showed proliferation-related MYC/E2F/G2M signatures. Together, these findings support tumor-wide upregulation of the TIGIT/CD155 axis in CRC and suggest that TIGIT, more than CD155, tracks with MSI/BRAF-associated immune activation, providing a rationale for patient stratification in checkpoint-directed immunotherapy.

P2, N=124, Recruiting, Alliance for Clinical Trials in Oncology | Trial primary completion date: Jan 2026 --> Jan 2027

These features often create diagnostic challenges during preoperative biopsy, intraoperative frozen section analysis, and postoperative histopathological evaluation. Herein, we report a rare case of recurrent, multifocal PSP exhibiting sarcomatoid features and harboring a p.E17K mutation in the AKT1 gene.

P2, N=33, Suspended, National Cancer Institute (NCI) | Recruiting --> Suspended

Lung cancer patients carrying co-occurrences of somatic mutation-CNVs in TP53 and KRAS showed poorer survival than those carrying the same gene mutations. These findings reveal epistasis of cancer mutations and CNVs at an allelic resolution, suggesting specific genomic events to enhance patient stratification and therapeutic targeting.

P2, N=45, Recruiting, National Human Genome Research Institute (NHGRI) | Trial completion date: Mar 2028 --> Jul 2028 | Trial primary completion date: Mar 2026 --> Jul 2026

Non-sinonasal ITACs are rare, aggressive malignancies requiring accurate diagnosis and further molecular investigation to improve management and outcomes.